Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin

BusinesswireMay 29 04:05

Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.

Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.

Dow JonesMay 14 00:47

HC Wainwright & Co. : Revance Therapeutics (RVNC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.

HC Wainwright & Co. : Revance Therapeutics (RVNC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.

Zhitong FinanceMay 14 00:40

Revance Therapeutics Is Maintained at Neutral by Goldman Sachs

Revance Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow JonesMay 14 00:03

Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8

Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics with a Neutral and lowers the price target from $9 to $8.

Analyst UpgradesMay 13 23:52

Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)

TipRanksMay 13 15:46